HIV VACCINE TRIAL RESULTS TO BE PRESENTED AT UPCOMING CONFERENCE

CytRx has announced that preliminary interim results from a novel polyvalent DNA + protein HIV vaccine Phase I clinical trial conducted at the University of Massachusetts Medical School will be presented at the AIDS Vaccine 2005 International Conference, to be held Sept. 6-9 in Montreal, Canada.

To date, the HIV vaccine project has been funded under a $16 million five-year HIV Vaccine Design and Development Team contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. An investigational new drug application relating to the clinical trial with the FDA became effective in March 2004. Patient enrollment in the three-arm Phase I clinical trial was completed in March 2005.